Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2025-2563

Published: 2025

Journal Articles

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Michael Wang, Jonas Paludo, João Samuel de Holanda Farias, Diego Villa, Cecily Forsyth, Ellie John, Menglu Che, Harneet Arora, Craig Delury, Victoria Otero, Yuqin Song

Blood (2025) 146 (Supplement 1): 885.

https://doi.org/10.1182/blood-2025-885

Published: 2025

Journal Articles

Large language model for abstraction of CAR-T therapy toxicities data

Blood (2025) 146 (Supplement 1): 6139.

https://doi.org/10.1182/blood-2025-6139

Published: 2025

Journal Articles

Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 5301.

https://doi.org/10.1182/blood-2025-5301

Published: 2025

Journal Articles

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Blood (2025) 146 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2025-6131

Published: 2025

Journal Articles

Reassessing pre-chemotherapy laboratory testing in R-CHOP: Are we doing too much?

Mohamed Warsame, Bolun Liu, Hadiyah Audil, Guleid Hussein, Sumeet Yadav, Alexander Xiao, Richard Godby, Jonas Paludo, Scott Soefje, Ronald Go

Blood (2025) 146 (Supplement 1): 6188.

https://doi.org/10.1182/blood-2025-6188

Published: 2025

Journal Articles

Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2025-5894

Published: 2025

Journal Articles

Genetic evolution of Waldenström macroglobulinemia across disease stages

Blood (2025) 146 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2025-3540

Published: 2025

Journal Articles

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 473.

https://doi.org/10.1182/blood-2025-473

Published: 2025

Journal Articles

Anatomical localization-based analysis of de novo secondary cns lymphoma

Izel Okcu, Zhuo Li, Launia White, Yucai Wang, Patrick Johnston, Allison Rosenthal, Arushi Khurana, Urshila Durani, Jonas Paludo, Rebecca King, Thomas Witzig, Thomas Habermann, Grzegorz Nowakowski, Han Tun

Blood (2025) 146 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2025-3675

Published: 2025

Journal Articles

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Julia Wang, Steven Hwang, Urshila Durani, Gita Thanarajasingam, Arushi Khurana, Jonas Paludo, Yucai Wang, Grzegorz Nowakowski, Thomas Habermann, Thomas Witzig, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2025-5399

Published: 2025

Journal Articles

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

Giuseppe Maiocco, Yoshito Nishimura, Guneet Janda, Yiqun Han, Urshila Durani, Grzegorz Nowakowski, Jonas Paludo, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5395.

https://doi.org/10.1182/blood-2025-5395

Published: 2025

Journal Articles

Clinics and clicks: Understanding hematology healthcare delivery utilization and preferences in the digital era

Rosalyn Marar, Nadia Toumeh, Savannah Liddell, Caleb Bentz, Damian Paulson, Hollie Stegemann, Jonas Paludo, Ronald Go, Richard Godby

Blood (2025) 146 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2025-2864

Published: 2025

Journal Articles

Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study

Jacqueline F. Wang, Jihao Zhou, Reema K. Tawfiq, Han W. Tun, Javier L. Munoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, Izel Okcu, Catherine S. Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang

Blood (2024) 144 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2024-204268

Published: 2024

Journal Articles

Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis

Shayna R Sarosiek, Monika Salkar, Barnabie Agatep, Barton Jones, Michelle Pacia, Chadi Saifan, Shaffee Bacchus, Sudeep Karve, Jonas Paludo

Blood (2024) 144 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2024-194639

Published: 2024

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia

Vaishali Bhardwaj, Zhi-Zhang Yang, Prithviraj Mukherjee, Rekha Mudappathi, Junewen Wang, Xinyi Tang, Jonas Paludo, Anne J. Novak, Patrizia Mondello, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2024-208966

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

Blood (2024) 144 (Supplement 1): 387.

https://doi.org/10.1182/blood-2024-194607

Published: 2024

Journal Articles

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2024-200290

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Large language model for abstraction of CAR-T therapy toxicities data

Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Reassessing pre-chemotherapy laboratory testing in R-CHOP: Are we doing too much?

Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma

Genetic evolution of Waldenström macroglobulinemia across disease stages

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Anatomical localization-based analysis of de novo secondary cns lymphoma

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

Clinics and clicks: Understanding hematology healthcare delivery utilization and preferences in the digital era

Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study

Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only